Oruka Therapeutics to Present at Piper Sandler’s 36th Annual Healthcare Conference
Oruka Therapeutics (Nasdaq: ORKA), a biotech company focused on developing novel biologics for chronic skin diseases including plaque psoriasis, has announced its upcoming participation at Piper Sandler's 36th Annual Healthcare Conference.
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Rhea-AI Summary
Oruka Therapeutics (Nasdaq: ORKA), a biotech company focused on developing novel biologics for chronic skin diseases including plaque psoriasis, has announced its upcoming participation at Piper Sandler's 36th Annual Healthcare Conference. The company will engage in a fireside chat scheduled for Tuesday, December 3rd, 2024, at 3:00 PM ET.
Details
News Market Reaction – ORKA
The recorded move for ORKA in the trading session of this news was +5.54%.
Data tracked by StockTitan Argus. Session date unavailable.
AI-generated analysis. How Rhea-AI works. Not financial advice.
MENLO PARK, Calif., Nov. 19, 2024 (GLOBE NEWSWIRE) -- Oruka Therapeutics, Inc. (“Oruka”) (Nasdaq: ORKA), a biotechnology company developing novel biologics designed to set a new standard for the treatment of chronic skin diseases including plaque psoriasis, today announced participation and a fireside chat at Piper Sandler’s 36th Annual Healthcare Conference:
Date: Tuesday, December 3rd, 2024
Time: 3:00PM ET
About Oruka Therapeutics
Oruka Therapeutics is developing novel biologics designed to set a new standard for the treatment of chronic skin diseases. Oruka’s mission is to offer patients suffering from chronic skin diseases like plaque psoriasis the greatest possible freedom from their condition by achieving high rates of complete disease clearance with dosing as infrequently as once or twice a year. Oruka is advancing a proprietary portfolio of potentially best-in-class antibodies that were engineered by Paragon Therapeutics and target the core mechanisms underlying plaque psoriasis and other dermatologic and inflammatory diseases. For more information, visit www.orukatx.com and follow Oruka on LinkedIn.
Investor Contact:
Alan Lada
(650)-606-7911
alan.lada@orukatx.com
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.